Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic.
作者信息
Ghajarzadeh Mahsa, Mirmosayyeb Omid, Barzegar Mahdi, Nehzat Nasim, Vaheb Saeed, Shaygannejad Vahid, Maghzi Amir-Hadi
机构信息
Universal council of epidemiology (UCE), universal scientific education and research network (USERN), Tehran University of medical sciences, Tehran, Iran.
Universal council of epidemiology (UCE), universal scientific education and research network (USERN), Tehran University of medical sciences, Tehran, Iran; Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran; Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
出版信息
Mult Scler Relat Disord. 2020 Aug;43:102222. doi: 10.1016/j.msard.2020.102222. Epub 2020 May 23.
Abstract
摘要
相似文献
1
Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic.一名多发性硬化症患者在大流行期间开始使用奥瑞珠单抗治疗，感染新冠病毒后预后良好。
Mult Scler Relat Disord. 2020 Aug;43:102222. doi: 10.1016/j.msard.2020.102222. Epub 2020 May 23.
2
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.B 细胞耗竭疗法可能会影响伊朗 COVID-19 疫情早期多发性硬化症患者急性呼吸道疾病的易感性。
Mult Scler Relat Disord. 2020 Aug;43:102195. doi: 10.1016/j.msard.2020.102195. Epub 2020 May 13.
3
Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab.两名接受奥瑞珠单抗治疗的多发性硬化症患者的 SARS-CoV-2 相关肺炎的轻度临床症状。
Mult Scler Relat Disord. 2020 Oct;45:102442. doi: 10.1016/j.msard.2020.102442. Epub 2020 Aug 4.
4
Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations.在新冠疫情期间治疗多发性硬化症患者：评估专家建议。
Mult Scler Relat Disord. 2020 Aug;43:102224. doi: 10.1016/j.msard.2020.102224. Epub 2020 May 23.
5
COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.新冠病毒肺炎在一名多发性硬化症患者中发作，该患者由于最近接受克拉屈滨治疗而出现严重的淋巴细胞减少症。
Mult Scler. 2020 Sep;26(10):1264-1266. doi: 10.1177/1352458520943783. Epub 2020 Aug 7.
6
Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.多发性硬化症患者在接受芬戈莫德治疗后感染严重 COVID-19。
Mult Scler Relat Disord. 2020 Jul;42:102180. doi: 10.1016/j.msard.2020.102180. Epub 2020 May 6.
7
Abnormal pulmonary function in COVID-19 patients at time of hospital discharge.COVID-19 患者出院时的肺功能异常。
Eur Respir J. 2020 Jun 18;55(6). doi: 10.1183/13993003.01217-2020. Print 2020 Jun.
8
Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression.阿仑单抗治疗新型冠状病毒肺炎大流行期间的多发性硬化症：尽管免疫抑制严重，但感染轻微且无并发症。
Mult Scler. 2020 Sep;26(10):1268-1269. doi: 10.1177/1352458520926459. Epub 2020 May 28.
9
A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19.微妙的平衡：免疫抑制与免疫疗法在多发性硬化合并 COVID-19 患者中的应用。
Mult Scler Relat Disord. 2020 Jul;42:102182. doi: 10.1016/j.msard.2020.102182. Epub 2020 May 8.
10
Ultrasound in COVID-19: a timeline of ultrasound findings in relation to CT.COVID-19中的超声检查：超声检查结果与CT相关性的时间线
Clin Radiol. 2020 Jul;75(7):553-554. doi: 10.1016/j.crad.2020.04.003. Epub 2020 Apr 18.
引用本文的文献
1
Immune responses following COVID-19 infection in multiple sclerosis patients using immunomodulatory therapy.COVID-19 感染后使用免疫调节疗法的多发性硬化症患者的免疫反应。
Acta Neurol Belg. 2023 Oct;123(5):1885-1892. doi: 10.1007/s13760-022-02125-6. Epub 2022 Nov 4.
2
The Outcome of COVID-19 in Patients with a History of Taking Rituximab: A Narrative Review.接受利妥昔单抗治疗的患者感染 COVID-19 的结局：一项叙述性综述。
Iran J Med Sci. 2021 Nov;46(6):411-419. doi: 10.30476/IJMS.2021.88717.1946.
3
The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic.控制多发性硬化症的免疫治疗策略：COVID-19 大流行期间的考虑因素。
Biomolecules. 2021 Sep 17;11(9):1372. doi: 10.3390/biom11091372.
4
COVID-19 severity and outcome in multiple sclerosis: Results of a national, registry-based, matched cohort study.COVID-19 严重程度和多发性硬化症结局：一项全国性、基于登记、匹配队列研究的结果。
Mult Scler Relat Disord. 2021 Oct;55:103217. doi: 10.1016/j.msard.2021.103217. Epub 2021 Aug 16.
5
Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations.多发性硬化症、疾病修正疗法与2019冠状病毒病：关于免疫反应和疫苗接种建议的系统综述
Vaccines (Basel). 2021 Jul 11;9(7):773. doi: 10.3390/vaccines9070773.
6
A New England COVID-19 Registry of Patients With CNS Demyelinating Disease: A Pilot Analysis.新英格兰 COVID-19 中枢神经系统脱髓鞘疾病患者注册研究：一项初步分析。
Neurol Neuroimmunol Neuroinflamm. 2021 Aug 2;8(5). doi: 10.1212/NXI.0000000000001046. Print 2021 Sep.
7
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19.COVID-19 大流行时期多发性硬化症奥瑞珠单抗延长给药间隔
Neurol Neuroimmunol Neuroinflamm. 2021 Jul 14;8(5). doi: 10.1212/NXI.0000000000001035. Print 2021 Sep.
8
SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry.西班牙神经病学学会登记处：多发性硬化症中的 SARS-CoV-2 感染结果。
Neurol Neuroimmunol Neuroinflamm. 2021 Jun 24;8(5). doi: 10.1212/NXI.0000000000001024. Print 2021 Jul.
9
COVID-19 Outcomes in Patients Undergoing B Cell Depletion Therapy and Those with Humoral Immunodeficiency States: A Scoping Review.接受B细胞耗竭疗法的患者和体液免疫缺陷状态患者的COVID-19结局：一项范围综述
Pathog Immun. 2021 May 14;6(1):76-103. doi: 10.20411/pai.v6i1.435. eCollection 2021.
10
COVID-19 illness and autoimmune diseases: recent insights.COVID-19 疾病与自身免疫性疾病：最新见解。
Inflamm Res. 2021 Apr;70(4):407-428. doi: 10.1007/s00011-021-01446-1. Epub 2021 Feb 28.
本文引用的文献
1
COVID-19 in persons with multiple sclerosis treated with ocrelizumab - A pharmacovigilance case series.接受奥瑞珠单抗治疗的多发性硬化症患者中的 COVID-19——一项药物警戒病例系列研究。
Mult Scler Relat Disord. 2020 Jul;42:102192. doi: 10.1016/j.msard.2020.102192. Epub 2020 May 16.
2
Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab.使用奥瑞珠单抗治疗的多发性硬化症患者中COVID-19的良性病程。
Mult Scler Relat Disord. 2020 Jul;42:102201. doi: 10.1016/j.msard.2020.102201. Epub 2020 May 15.
3
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.B 细胞耗竭疗法可能会影响伊朗 COVID-19 疫情早期多发性硬化症患者急性呼吸道疾病的易感性。
Mult Scler Relat Disord. 2020 Aug;43:102195. doi: 10.1016/j.msard.2020.102195. Epub 2020 May 13.
4
Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain.多发性硬化症及相关疾病中的抗CD20与COVID-19：来自西班牙马德里的60例患者病例系列
Mult Scler Relat Disord. 2020 Jul;42:102185. doi: 10.1016/j.msard.2020.102185. Epub 2020 May 7.
5
SARS-CoV-2 and Multiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad.严重急性呼吸综合征冠状病毒2与多发性硬化症：并非所有免疫耗竭性疾病修正治疗药物都是相同的或有害的。
Ann Neurol. 2020 Jun;87(6):794-797. doi: 10.1002/ana.25770.
6
COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.一名接受芬戈莫德治疗的多发性硬化症患者感染了新冠病毒。
Neurol Neuroimmunol Neuroinflamm. 2020 May 5;7(4). doi: 10.1212/NXI.0000000000000753. Print 2020 Jul.
7
An Italian programme for COVID-19 infection in multiple sclerosis.一项针对多发性硬化症患者新冠病毒感染情况的意大利项目。
Lancet Neurol. 2020 Jun;19(6):481-482. doi: 10.1016/S1474-4422(20)30147-2. Epub 2020 Apr 30.
8
Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19.抗CD20免疫抑制疾病改善疗法与新型冠状病毒肺炎
Mult Scler Relat Disord. 2020 Jun;41:102135. doi: 10.1016/j.msard.2020.102135. Epub 2020 Apr 18.
9
COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?奥瑞珠单抗治疗多发性硬化症患者合并 COVID-19：免疫抑制是否具有保护作用？
Mult Scler Relat Disord. 2020 Jul;42:102120. doi: 10.1016/j.msard.2020.102120. Epub 2020 Apr 15.
10
Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection.胸部计算机断层扫描在 2019 年冠状病毒病（COVID-19）中的表现：与感染持续时间的关系。
Radiology. 2020 Jun;295(3):200463. doi: 10.1148/radiol.2020200463. Epub 2020 Feb 20.
Zotero 插件